TBPH — Theravance Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1583107 ·
Last close
$16.41
Market Cap
$845.98M
52W High
$19.37
52W Low
$13.08
ADV30
358,499
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 17,699,000 | — | -5,850,000 | -4,933,000 | 472,313,000 | 288,101,000 | 181,719,000 |
| Dec 2025 | 45,891,000 | — | 20,011,000 | 61,024,000 | 485,570,000 | 167,806,000 | 188,847,000 |
| Sep 2025 | 19,990,000 | — | -6,455,000 | 3,615,000 | 415,460,000 | 174,773,000 | 182,779,000 |
| Jun 2025 | 26,195,000 | — | -2,725,000 | 54,835,000 | 426,035,000 | 281,927,000 | 201,187,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$238,541,000
Investing CF
$-105,284,000
Financing CF
$-3,248,000
CapEx
$-213,000
Dividends Paid
—
Buybacks
$-4,034,000
EPS Diluted TTM
$2.03
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-859,627,000
Inventory
—
Receivables
$95,539,000
ST Investments
$147,551,000
EBIT TTM
$131,708,000
Pretax Income TTM
$129,247,000
Interest Exp TTM
$2,461,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$109,775,000
EBITDA
$6,576,000
Free Cash Flow
$22,506,500
Enterprise Value
$491,822,816
Total Cash
$394,665,984
Total Debt
$40,504,000
Shares Out
51,553,005
Trailing EPS
$2.23
Book Value
$5.81
ROE
50.2%
ROA
0.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 107,464,000 | -3,602,000 | 105,895,000 | 485,570,000 | 188,847,000 | — | 238,541,000 |
| Dec 2024 | 64,381,000 | -42,436,000 | -56,418,000 | 354,161,000 | 178,616,000 | — | -11,535,000 |
| Dec 2023 | 57,424,000 | -53,292,000 | -55,193,000 | 381,999,000 | 169,004,000 | — | -26,997,000 |
| Dec 2022 | 51,346,000 | -79,119,000 | 872,132,000 | 607,400,000 | 165,600,000 | — | -186,991,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $844.44M | $86.28 | — |
| OMER | OMEROS CORP | $843.17M | $11.65 | — |
| AVTX | Avalo Therapeutics, Inc. | $842.10M | $16.02 | — |
| EVMN | Evommune, Inc. | $841.03M | $23.35 | — |
| ETON | Eton Pharmaceuticals, Inc. | $857.11M | $31.29 | — |
News headlines (Yahoo Finance, 1h cache)
Are Options Traders Betting on a Big Move in Theravance Biopharma Stock?
2026-05-13 13:27 · Yahoo
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
2026-05-08 17:26 · Yahoo
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-07 12:30 · Yahoo
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
2026-05-06 21:10 · Yahoo
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised
2026-05-01 15:15 · Yahoo
Laughing Water Capital’s New Position: Theravance Biopharma (TBPH)
2026-04-24 14:27 · Yahoo
B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14
2026-04-20 00:09 · Yahoo
Theravance Stock Declines Around 17% in Three Months: Here's Why
2026-04-16 17:13 · Yahoo
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
2026-04-06 15:10 · Yahoo
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
2026-04-02 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.